Samsung Bioepis, Biogen, and Fujifilm Kyowa Kirin Biologics are seeking to invalidate some of AbbVie’s patents related to Humira® (adalimumab) before the UK High Court of Justice.  The patents at issue relate to methods of treatment.  AbbVie attempted to have the case dismissed after offering to abandon the patents at issue, but the UK High Court held that the case should go forward, due in part to the need for commercial certainty.

AbbVie’s U.S. Humira patent portfolio is also subject to challenges through IPRs filed by Coherus and district court litigation against Amgen.

Big Molecule Watch will continue to follow this case and other litigation involving biosimilars, so check back for the latest news and analysis.